REFRACTORY MYELODYSPLASTIC SYNDROME

This study is testing a new combination of three drugs—navitoclax, venetoclax, and decitabine—for patients with a high-risk type of blood and bone marrow cancer called myelodysplastic syndrome (MDS) that has come back or hasn't responded to standard treatments. The main goals are…

This early-stage study is testing the safety and best dose of a two-drug combination for people with aggressive forms of blood cancer (myelodysplastic syndrome or acute myeloid leukemia) that have returned or not responded to prior treatments. The trial combines a chemotherapy dr…

This early-stage trial is testing whether a radioactive antibody called lintuzumab-Ac225 can help control advanced myelodysplastic syndrome (MDS) that hasn't responded to standard treatments. The treatment works by attaching to cancer cells and delivering radiation directly to th…

This early-stage study is testing a new drug called uproleselan, given with two standard chemotherapy drugs, for children and teenagers with aggressive forms of leukemia that have come back or stopped responding to treatment. The main goals are to find the safest dose and see how…

This study is testing if a pill called olaparib can help control advanced blood cancers (acute myeloid leukemia or myelodysplastic syndrome) that have come back or haven't responded to standard treatments. It is for adults whose cancer has a specific genetic change called an IDH …

This study is testing a new combination of two drugs, venetoclax and azacitidine, for patients with high-risk myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) that has come back or stopped responding to standard treatment. The first part of the study aims …

This early-stage study is testing the safety and best dose of a new three-drug combination for adults with acute myeloid leukemia (AML) or related blood cancers that have come back or not responded to prior treatments. The goal is to see if adding the drug regorafenib to two exis…